HQIP / Resources / National clinical audit of biological therapies – UK inflammatory bowel disease (IBD) audit
National clinical audit of biological therapies – UK inflammatory bowel disease (IBD) audit
Published: 22 Sep 2016
The purpose of this audit is to measure the efficacy, safety and appropriate use of biological therapies in patients with IBD in the UK. The audit also aims to capture patients’ views on their quality of life at intervals during their treatment.
This is the fifth report of the biological therapy element of the UK IBD audit; all analyses within this report include only those patients who were newly started on biological therapies between 12 September 2011 (the start of data collection) and 29 February 2016. The data contained within this report have only been taken from completed submissions within the biological therapy audit web tool (www.ibdbiologicsaudit.org).